Keyword: Concert Pharmaceuticals
Two dose levels of Concert's alopecia drug beat placebo in phase 2, teeing it up to enter phase 3 in 2020.
Concert Pharmaceuticals’ alopecia drug reduced disease severity in nearly half of the patients who received a higher dose.
The setback leaves Concert committed to taking the drug forward in alopecia areata but uncertain of its future beyond the indication.
Lilly's longtime CFO Rice will retire, Akari's CEO resigned amid a false data scandal, MannKind replaced its CEO with the hope to revive Afrezza.
Concert Pharmaceuticals' just-started phase 2a trial of its baldness candidate CTP-543 has been halted by an FDA request to look at preclinical toxicity data.
Vertex could pay out as much as $250 million to gain full access to Concert Pharmaceuticals’ midstage cystic fibrosis candidate CTP-656, a tweaked version of its own Kalydeco, as it eyes combo uses that target the underlying causes of the fatal disease.